MorphoSys AG
FRANKFURT : MOR

April 18, 2012 02:03 ET

MorphoSys AG: Announcement of the Convening of the General Meeting in Munich/Germany on 31/5/2012 according to 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution

MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - Apr 18, 2012) -

MorphoSys AG / MorphoSys AG: Announcement of the Convening of the General Meeting in Munich/Germany on 31/5/2012 according to §121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG
Martinsried/Planegg
Securities' code numbers: 663200 and A1MBF5
ISIN: DE0006632003 and DE000A1MBF50

Reading and Convenience Translation

Invitation to the Annual Shareholders' Meeting 2012

We hereby invite the shareholders of our Company to the Annual Shareholders' Meeting which is taking place on May 31, 2012 at 10:00 a.m., in the Conference Centre Munich, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636 Munich.

Agenda

1. Presentation of the confirmed annual financial statements as of December 31, 2011, the management report together with the consolidated financial statements, the consolidated management report and the report of the Supervisory Board for the business year 2011 and the statement of the Board of Management to the items pursuant to § § 289 para. 4, 315 para. 4 HGB

2. Resolution on the use of the net earnings of MorphoSys AG Resolution on the formal approval on behalf of the Board of Management

3. Resolution on the formal approval on behalf of the Supervisory Board

4. Resolution on the appointment of the auditors for the business year 2012

5. Resolution on the new election of supervisory board members

6. Resolution on the deletion of the Authorized Capital 2008-I and creation of a new Authorized Capital 2012-I with the possibility to exclude pre-emptive rights of the shareholders; amendment of the Articles

7. Resolution on the deletion of the Authorized Capital 2008-II and creation of a new Authorized Capital 2012-II with the possibility to exclude pre-emptive rights of the shareholders; amendment of the Articles

8. Resolution on the compensation of the Supervisory Board

Please find the full text of the announcement here: www.morphosys.com/agm

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company's AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1603374]

Contact Information

  • For more information, please contact:

    MorphoSys AG
    Dr. Claudia Gutjahr-Loser
    Head of Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-122

    Mario Brkulj
    Senior Manager Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-454

    Jessica Kulpi
    Specialist Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-332

    Email Contact